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€17.570/LYG. CONCLUSIONS: It was possible to develop a unique base case
Markov model for early breast cancer from the literature and to adjust this
model taking various published assumptions into account. The adaptation of
various assumptions resulted in differences in outcomes of CEAs of adjuvant
breast cancer therapies. This case example demonstrates the importance of the
development of standardized model structures for adjuvant breast cancer ther-
apies.
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OBJECTIVES: Breast cancer is the most common malignant disease in Western
women. In the ONCOTYROL research center, a Breast Cancer Outcomes & Policy
(ONCOTYROL) model was developed to evaluate the cost-effectiveness of the
new 21-gene assay that supports personalized decisions on adjuvant chemo-
therapy. The goal of this study was to validate our Oncotyrol-model. METHODS:
The 21-gene assay was evaluated by simulating a hypothetical cohort of 50-year
old women over a lifetime time horizon using a discrete event simulation. Main
model outcomes were life-years gained, quality-adjusted life-years (QALYs) and
costs. Based on the new ISPOR-SMDM best practice recommendations, the
model has been validated. Major focus was on our experiences of the cross
validation, i.e. the comparison of modeling results between the discrete-event-
simulation ONCOTYROL-model and the THETA-model (Toronto Health Eco-
nomics and Technology Assessment Collaborative) which is a Markov model.
Therefore, the Oncotyrol-model has been populated with the Canadian THETA-
model parameters. Cross validation started with a comparison of the natural
history followed by QALYs and costs. RESULTS: The relative differences varied
among the model outcomes. The smallest differences we found for costs, the high-
est for QALYs. All differences were smaller than 2.5%. The comparison of the effi-
ciency frontiers showed that small differences due to the modeling approach can
lead to a different set of non-dominated test-treatment strategies. The cross model
validation involved several challenges: distinguishing between outcomes differ-
ences due to different modeling techniques and errors, definitions for meaningful
differences and comparison techniques (mean estimates, distributions, multivar-
iate outcomes). CONCLUSIONS: Cross-model validation was crucial to identify and
correct modeling errors and to explain remaining differences of modeling results.
However, small differences can lead to relevant changes in cost-effectiveness re-
sults.
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OBJECTIVES: Compliance and treatment duration can have a significant impact
on costs and health outcomes in health-economic assessments, especially in
high-cost therapy areas such as oncology. The objective of this study was to
systematically review different methods for addressing treatment compliance
and discontinuation in oncology economic models, critique the identified meth-
odologies, and highlight best practices. METHODS: A systematic review was un-
dertaken to investigate the different methods that could be used to include com-
pliance and treatment discontinuation in economic modelling in oncology
populations. MEDLINE, Embase, EconLit and the Cochrane Library (from 2000 on-
wards), and technology assessment documents and manufacturer submissions to
the National Institute for Health and Clinical Excellence (NICE) were searched for
economic analyses which mentioned compliance or discontinuation. Results were
filtered using pre-specified selection criteria and data extracted into a pre-defined
template. RESULTS: Sixty-eight publications of 51 models were included, compris-
ing 20 journal publications and 48 technology appraisal documents. Possible meth-
ods were divided into ten categories. Seven studies mentioned discontinuations,
but did not include a modelling approach. There was a lack of consensus regarding
the methods applied. Twenty studies varied dose or discontinuation rate in sensi-
tivity analyses, although impact on overall outcomes was rarely explored. Dose
intensity was most often adopted from clinical trials. Effects on the overall out-
comes by inclusion of discontinuations or dose intensity adjustments were rarely
discussed. Overall, the authors of included publications poorly justified their meth-
ods regarding compliance assumptions. CONCLUSIONS: The combination of sev-
eral methods could improve accuracy of modelling discontinuations. Discontinu-
ations should affect three aspects of the model: transition probabilities, costs and
effects. Clear explanations and justification of the included parameter assump-
tions should also be improved in NICE submissions to enhance likelihood of posi-
tive recommendation. Standardised guidelines could raise more attention to com-
pliance in economic modelling and could improve the accuracy of economic
models.
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OBJECTIVES: The UK NHS is currently undergoing the most significant reforms to
its structure possibly since the NHS was formed. There are many questions at all
levels regarding the reforms, and this research aimed to address some of them The
objectives were – 1) To assess how the reforms were proceeding and what issues
they had been encountered, and 2) To determine how the delivery of care has been
impacted at a grassroots level.METHODS:We adopted a two phased approach. The
first phase involved extensive literature review in order to assess how the reforms
were expected to proceed, what the outcomes were likely/expected to be and when
key milestones were expected to be met. The second phase was centred on primary
research carried out by Double Helix personnel. Key stakeholders in the reforming
NHS at all levels were approached and data was collected using a combination of
qualitative and quantitative methodologies. RESULTS:While the vision of the NHS
reforms was very clear from the outset, the actual progression on the ground has
been met with considerable challenges. Even while CCGs in the first wave were in
the process of undergoing assessment, changes to the overall architecture of the
reforms were continuous. Key personnel at all levels lacked a clear grasp of what
the following 12 months would bring, and various influencer and guideline bodies
faced uncertain futures or lacked a clear remit. At the stage of writing there was no
clear evidence either way to suggest that the reforms were having an impact on
frontline health care delivery. CONCLUSIONS: The UK NHS Reforms were always
going to be challenging due to their scale and complexity. However there has been
a clear lack of direction at various levels leading to uncertainty and fears for the
short and medium term future.
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OBJECTIVES: Early development of HTA in Italy has been mainly hospital-based
(HB HTA). HB HTA can support administrative procedures increasing transparency
and promoting the bottom-up awareness around HTA principles. Whether HTA
has an impact on actual hospital expenditure and consumption of health technol-
ogies, particularly medical devices (MDs), has not been investigated. This research
aimed at exploring potential HB HTA’s impact on purchased MDs, once assessed its
diffusion in Italy. METHODS: We run a survey, based on a semi structured on line
questionnaire, on a sample of Italian Healthcare trusts, asking for 2008-2009 data
about consumption and unitary costs of a class of MDs (e.g. coronary stents) and
HTA activities. HB HTA’s activities have been surveyed in terms of diffusion and
structural/organizational characteristics. We assessed in a multivariate analysis
whether an association exists between the implementation of HTA activities and
MDs diffusion at the local level. RESULTS: Given 46 respondents, located in 15
Italian Regions, 22 (48%) have a commission for MDs. Commissions meet almost
monthly and encompass on average 10 members (SD5.4). On average there are 2
pharmacists (SD1.13); 3 medical doctors (SD2.91) and 1 clinical engineer
(SD2.9). About 60% of the Commissions produce evaluation forms and repertory,
whereas about 40% produce hospital guidelines and other documents to support
procurement activities. A preliminary analysis of HB HTA’s characteristics shows
that the perception on the importance of HTA in a hospital may depend on the
presence/absence of the organizational structure (such as defined HTA Commis-
sion) and a correlation exists between expenditures/volumes of coronary stents
and level of importance of “economic” aspects in HTA. CONCLUSIONS:We suggest
HTA could potentially impact on health technologies’ uptake and expenditure
when realized within the hospital setting, stimulating collaboration between dif-
ferent units and actors, thus providing local health care managers with a useful
tool for budget control and planning.
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OBJECTIVES: Cataract surgery is commonly performed in developed countries.
Artificial lens implantation is considered to be one of the most cost-effective med-
ical interventions. The aim of this analysis was to describe the organization of
cataract surgery in Poland and compare access and quality of care with other
countries. METHODS: Access to cataract surgeries was assessed on the base of
statistical reports issued by National Health Fund (NHF) regarding number and
structure of cataract surgeries and waiting times. Epidemiological data was used to
estimate number of patients qualifying for treatment. Data on reimbursement was
obtained from Ministry of Health and NHF. To supplement publicly available data,
a number of clinical experts were consulted. RESULTS: Each year 170k cataract
surgeries are reimbursed in Poland. 300k patients are currently in a queue for
surgery. The mean waiting time is geographically dependent and varies from 8 up
to 22 months (stable cases). There is a high disproportion among voivodeships in
funding of cataract surgeries. The Cataract Surgery Rate (CSR) in 2011 was 4.4k
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surgeries per 1m of population in Poland, while the mean CSR in the European
Union in 2008 was 7.6k. The number of ophthalmologists in Poland is 10 times
higher than in India, while the CSR is lower by 25%. The average percentage of
day-case cataract surgeries in OECD countries is 85%, and in Poland this number is
as low as 15%. CONCLUSIONS: Poland is a country with poor, ineffective organiza-
tion of cataract surgeries and has one of the worst access to these procedures in
Europe. Actions aimed at improvement of access must be undertaken, otherwise
the situation will rapidly deteriorate due to aging of population.
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OBJECTIVES: Home dialysis is associated with significant benefits for patients
and health care systems, but its usage varies greatly across Europe. Population
characteristics (especially age) are often proposed as an explanation of this
variation. The aim of this analysis was to estimate the number of potential
peritoneal dialysis (PD) patients based on the current age distribution of end
stage renal disease (ESRD) patients in 14 European countries and the highest
usage of PD per age group among these countries (assuming health status per
age groups is similar across countries). METHODS: The age distribution of ESRD
patients and PD usage per age group were extracted from the 2009 European
Renal Association – European Dialysis and Transplant Association registry re-
port. The highest PD usage values in each age group of incident and prevalent
patients were applied to the overall age distribution of ESRD patients in the 14
countries to obtain an estimate of the potential number of PD patients. Differ-
ences with the current 2009 numbers were computed. RESULTS: Overall in 2009,
there were 5005 incident PD patients (15.8% of ESRD, 16.5% of dialysis patients) and
17175 prevalent patients (7.2% of ESRD, 12.2% of dialysis patients). The highest
proportion of PD patients in the 20-44, 45-64, 65-74, and 75  age groups were
respectively 55%, 39%, 34% and 32% of incident and 11%, 14%, 17% and 26% of
prevalent ESRD patients. Applying the highest proportions to the current age dis-
tribution of ESRD patients showed that an additional 6764 incident and 22272 ad-
ditional prevalent ESRD patients could potentially be treated at home with PD.
CONCLUSIONS: This analysis shows that in the group of 14 countries studied,
provided health status per age group is similar across countries, several thousand
more ESRD patients could be treated at home and benefit from the flexibility and
autonomy of such treatment.
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OBJECTIVES: Currently, quality of life (QOL) utilities can be derived from both
generic QOL questionnaires and disease-specific questionnaires. The cancer-spe-
cific questionnaire QLQ-C30 has been mapped onto the EQ5D and has been valued
in a time-trade-off (TTO) study. The aim of this study was to compare utilities from
the EQ5D-5L with the utilities from the QLQ-C30 in acute leukemia patients.
METHODS: Analyses were performed on cross-sectional data collected from 86
acute leukemia patients who completed both EQ5D-5L and QLQ-C30. The cross-
walk value set was used to calculate EQ5D-5L utilities. The descriptive systems and
utility scores of the EQ5D-5L and QLQ-C30 were compared by evaluating mean and
median scores, range, floor and ceiling effects, correlations between utilities and
the ability to discriminate between patients who were able/unable to work.
RESULTS: Mean utility scores were 0.82, 0.82 and 0.85 for the EQ5D-5L, QLQ-C30-
mapping and QLQ-C30-TTO, respectively. The QLQ-C30-TTO utility score was sig-
nificantly higher than the other two utility scores. Utility scores ranged from 0.21-
1.0 for the EQ5D-5L and QLQ-C30-mapping and from 0.51-1.0 for the QLQ-C30-TTO.
The percentage of patients with a utility score of 1 was significantly higher with the
EQ5D-5L than with the QLQ-C30. Both the QLQ-C30 and the EQ5D-5L were able to
discriminate between patients who were able/unable to work.CONCLUSIONS:QOL
utilities for acute leukemia can adequately be calculated from both QLQ-C30-map-
ping and EQ5D-5L. In future studies, choice of QOL questionnaire should depend
upon the expected differences in health between interventions because mild
health problems are better detected by the QLQ-C30.
UT2
MAPPING DLQI ON EQ-5D IN PSORIASIS – TRANSFORMATION OF SKIN-SPECIFIC
HEALTH-RELATED QUALITY OF LIFE INTO UTILITIES
Blome C1, Beikert F1, Rustenbach SJ1, Augustin M2
1University Medical Center Hamburg, Hamburg, Germany, 2University Clinics of Hamburg,
Hamburg, Germany
OBJECTIVES: In many countries, utility measures are required for allocation deci-
sions. Unlike the EQ-5D (EuroQoL-5D), the DLQI (Dermatology Life Quality Index)
has not been developed for the derivation of utilities. Purpose of this study was to
develop and test an algorithm for the transformation of DLQI scores into EQ-5D
utility scores. METHODS: Pre-existing data of two cross-sectional studies (for de-
velopment, n  1,511; for cross-validation n  2,009) of German psoriasis patients
were reanalyzed. Both EQ-5D global score and EQ-5D visual analogue scale (VAS)
were used as utility measures. Correlations were computed to identify predictors of
EQ-5D utility scores. Linear stepwise regressions were conducted using DLQI and
further potential predictors to find the optimal mapping algorithm. RESULTS: Us-
ing only DLQI as predictor resulted in coefficients of determination of R2  0.235
(EQ-5D global score) and R2  0.242 (EQ-5D VAS). In the final algorithm, seven
predictors were included which correctly predicted EQ-5D VAS for 60.4% (develop-
ment database) and 60.8% of all patients (cross-validation database) within a range
of 15 units. The algorithm explained 31.3% of the EQ-5D variance in the develop-
ment database and 26.8% in the cross-validation database. CONCLUSIONS: In spite
of the wide definition of correct prediction (15 units), utility scores of less than
two thirds of the patients were predicted correctly. As opposed to the authors of
two publications on earlier mapping approaches, we therefore conclude that map-
ping of DLQI on EQ-5D in psoriasis patients has considerable limitations in validity
and clinical relevance.
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OBJECTIVES: To help facilitate economic evaluations of interventions for treating
cancer, we estimated utility indices for the frequently used cancer-specific instru-
ment of quality of life, by mapping it onto each of the HUI-2 and HUI-3 general
health preference-based indices. METHODS: A sample of 367 cancer patients from
the Vancouver Cancer Centre completed the FACT-G, HUI-2 and HUI-3 health-
related quality of life questionnaires. Models of the relationships between the
FACT-G and each of the preference based indices were estimated using regression
analyses. We examined three alternative modeling approaches: ordinary-least-
squares (OLS); generalized-linear-modeling (GLM) using a Gaussian distribution
and log link; and censored-least-absolute deviations (CLAD). The performance of
the models was assessed in terms of how well the responses to the cancer-specific
instrument predicted utilities from each of the preference-based instruments us-
ing the mean absolute error (MAE) and root mean square error (RMSE). We adjusted
for the socio-demographic and clinical characteristics of patients. RESULTS: Re-
sults from the final models of the three approaches did not differ significantly.
Physical, functional and emotional subscales of the FACT-G were significant pre-
dictors of the HUI-2 and HUI-3 utility scores. The root mean square error for the
HUI-3 was lower, suggesting better predictions than for the HUI-2. The OLS/GLM
predicted HUI-2 and HUI-3 scores matched the observed values more closely than
the CLAD. CONCLUSIONS: There is potential to estimate both HUI-2/HUI-3 utilities
using responses from the FACT-G cancer-specific measure of quality-of-life, even
though it was not designed as a utility instrument. Our results suggest that it is
possible to estimate Quality-Adjusted-Life-Years from studies where only cancer-
specific instruments have been administered.
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OBJECTIVES: The Health Utilities Index-Mark 2 (HUI-2) is a generic preference-
based assessment for measuring general health status. The aim is to describe
HUI-2 utility data from a European, phase 3 clinical trial of the prodrug stimulant
lisdexamfetamine dimesylate (LDX) in children and adolescents with attention-
deficit/hyperactivity disorder (ADHD). METHODS: A 7-week, randomized, double-
blind, placebo-controlled trial of an optimized once-daily dose of LDX (30mg, 50mg,
70mg) was conducted in patients (6–17 years) with ADHD. Osmotic release oral
system methylphenidate (OROS-MPH) was included as a reference arm. HUI-2 was
administered by the parent at baseline (day 0), visit 4 (day 28) and visit 7 (day 49). A
multi-attribute utility function based on the 15 health status questions of HUI-2
was determined for treatment responders and non-responders, when response
was defined as a clinical global impressions-improvement (CGI-I) score of 1 or 2, a
reduction from baseline in ADHD-rating scale (ADHD-RS) score of 25% or a
reduction from baseline in ADHD-RS score 30%. Endpoint was defined as the
last on-treatment visit at which a valid HUI-2 score was obtained. RESULTS: Of 336
randomized patients, 317 were included in the full analysis set (LDX, n104; pla-
cebo, n106; OROS-MPH, n107) and 196 patients completed the study. At end-
point and across all treatment groups, HUI-2 utility scores were higher for respond-
ers than non-responders when response was based on a CGI-I score 1 or 2 (0.895
[0.099], n287 vs 0.839 [0.142], n169), a reduction from baseline in ADHD-RS score
of25% (0.899 [0.097], n338 vs 0.809 [0.147], n115) or a reduction from baseline
in ADHD-RS score of 30% (0.902 [0.094], n322 vs 0.814 [0.148], n131).
CONCLUSIONS: In this short-term trial of LDX in children and adolescents with
ADHD, symptomatic response was reflected in better utility scores than non-re-
sponse. Supported by funding from Shire Development LLC.
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